MANKIND - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | MANKIND | Market Cap | 92,750 Cr. | Current Price | 2,247 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 52.5 | Book Value | 376 ₹ | Dividend Yield | 0.04 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,143 ₹ | DMA 200 | 2,244 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 63.8 | MACD | 50.1 | Volume | 3,09,556 | Avg Vol 1Wk | 3,26,436 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.24 | Debt to equity | 0.47 |
| 52w Index | 41.2 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 30.1 |
📊 Mankind Pharma (MANKIND) shows decent fundamentals but trades at stretched valuations. With a market cap of ₹92,750 Cr. and current price of ₹2,247, the stock is near its 200 DMA (₹2,244) and above its 50 DMA (₹2,143). Efficiency metrics are moderate — ROE at 13.9% and ROCE at 15.0% — while valuation is expensive with a P/E of 52.5 compared to the industry average of 30.1. EPS at ₹41.3 is stable, supported by quarterly PAT growth (+24.5%). Debt-to-equity at 0.47 is manageable, but PEG ratio at 6.24 highlights overvaluation relative to growth. Dividend yield remains negligible at 0.04%. Technical indicators (RSI 63.8, MACD positive) show momentum, though FIIs reduced holdings (-1.10%) while DIIs increased (+1.20%).
💡 Entry Zone: ₹2,150–₹2,200 (near DMA support)
📈 Long-Term Holding: Suitable for cautious accumulation, but valuations are stretched. Investors should monitor earnings consistency and sector growth before committing to long-term positions.
✅ Positive
- Quarterly PAT growth (+24.5%) shows earnings momentum
- EPS of ₹41.3 supports earnings visibility
- Debt-to-equity ratio (0.47) remains manageable
- DII holdings increased (+1.20%), showing domestic confidence
- Technical indicators (RSI 63.8, MACD positive) support bullish momentum
⚠️ Limitation
- High valuation (P/E 52.5 vs industry 30.1)
- PEG ratio (6.24) highlights poor growth-adjusted valuation
- Dividend yield negligible at 0.04%
- FIIs reduced holdings (-1.10%), showing weaker foreign confidence
📉 Company Negative News
- Valuation stretched compared to sector peers
- Weak efficiency metrics relative to premium valuation
📈 Company Positive News
- PAT improved significantly (₹459 Cr → ₹513 Cr)
- DII support increased (+1.20%)
- Stock trading above DMA 50 and DMA 200, showing technical strength
🏭 Industry
- Pharma sector trades at lower P/E (30.1), making Mankind relatively expensive
- Sector outlook remains positive with demand for generics and specialty drugs
🔎 Conclusion
Mankind Pharma is fundamentally stable with strong earnings growth and manageable debt, but valuations are stretched. Entry near ₹2,150–₹2,200 offers a risk-managed opportunity. Long-term investors should accumulate cautiously, focusing on earnings consistency and sector expansion before committing to larger positions.